Jason Gotlib, MD
AIM President/ Stanford University/ Stanford Cancer Institute
Dr. Gotlib is Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine/ Stanford Cancer Institute. His research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, with a focus on KIT inhibitors for systemic mastocytosis (SM). Dr. Gotlib has authored more than 250 research articles, chapters, and reviews that have been published in journals such as Blood, Journal of Clinical Oncology, Nature Medicine, and The New England Journal of Medicine.
He is Vice-Chair of the NCCN Guidelines Committee on Myeloproliferative Neoplasms and chaired the NCCN guideline development for SM. He led the clinical development of midostaurin and avapritinib for patients with advanced SM, as well as response criteria for these diseases which are used by regulatory agencies for drug approval.
Dr. Gotlib was awarded the European Competence Network on Mastocytosis (ECNM) Medal as Researcher of the Year in 2019 for the development of KIT-targeting therapies in advanced SM. He currently serves as President of the American Initiative in Mast Cell Diseases (AIM). Dr. Gotlib enjoys landscape photography in his spare time.